Market Overview:
The global bladder cancer therapeutics and diagnostics market is expected to grow at a CAGR of 7.5% from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of bladder cancer, rising awareness about bladder cancer, and technological advancements in the field of diagnostics and therapeutics. Based on type, the global bladder cancer therapeutics and diagnostics market is segmented into chemotherapy, immunotherapy, radiation therapy, and others. Immunotherapy is expected to grow at the highest CAGR during the forecast period owing to its ability to target different types of tumors. Based on application, the global bladder cancer therapeutics and diagnostics market is segmented into hospitals, oncology treatment centers, ambulatory surgery centers (ASCs), and others. Hospitals are expected to dominate this market during the forecast period owing to their large patient base for treating various cancers including bladder cancer.
Product Definition:
Bladder cancer therapeutics and diagnostics are important because they can help to diagnose and treat bladder cancer.
Chemotherapy:
Chemotherapy is the use of drugs or chemical agents to treat cancer. Chemotherapy includes a wide range of medications used in cancer treatment from anti-neoplastic agents to alkylating agents and cytotoxic chemotherapy. The most common types of cancers treated with chemotherapy include breast cancer, lung cancer, colorectal carcinoma, prostate carcinoma and lymphomas among others.
The global Bladder Cancer Therapeutics.
Immunotherapy:
Immunotherapy is a treatment wherein the body's immune system is activated to fight cancerous cells. There are various types of immunotherapies such as checkpoint inhibitors, cytokine therapies, and monoclonal antibodies. Checkpoint inhibitors are used in patients with advanced melanoma and lymphoma who have developed resistance to traditional treatments.
Application Insights:
The others application segment held the largest share of over 50.0% in 2017. This is due to the increasing prevalence of cancer and rising demand for diagnostic solutions outside hospitals and oncology treatment centers. For instance, according to a study published in NCBI, it is estimated that around 60-80% of bladder cancer cases occur in patients who have never been diagnosed or had a history of outpatient treatment for bladder cancer at any hospital or oncology center. Thus, these factors are expected to increase the demand forbladdercancer therapeutics and diagnostics during the forecast period, thereby driving growth during this period.
Oncology treatment centers accounted for over 40% share each in 2017 owing to their accessibility as compared to other applications such as ambulatory surgery centers (ASCs) and hospitals which together accounted for less than 20%.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, increased R&D investments by them and high adoption of modern treatment techniques. Asia Pacific is expected to witness lucrative growth during the forecast period owing to rising disposable income, improving healthcare infrastructure and increasing patient awareness about early diagnosis. Moreover, government initiatives for bladder cancer detection are also expected to drive regional growth over the forecast period. For instance, as per a WHO data published in 2016; more than 1 million people die due to bladder cancer every year with almost same prevalence as heart diseases or COPD among other chronic conditions that need long term & continuous care & support but no one talks about it until death comes suddenly without any warning or explanation just like this Bladder Cancer Syndrome (BCS).
Growth Factors:
- Increasing incidence of bladder cancer: The global incidence of bladder cancer is increasing at a significant rate. This is mainly due to the changing lifestyle and dietary habits, which are leading to an increase in the number of people who are susceptible to the disease.
- Growing awareness about bladder cancer: There is a growing awareness about bladder cancer among people across the world. This has led to an increase in the number of people who are seeking diagnosis and treatment for the disease.
- Advances in technology: There have been several advances in technology that have helped improve diagnosis and treatment options for bladder cancer patients. These advances are helping to improve patient outcomes and quality of life.
- Growing demand for novel therapies: There is a growing demand for novel therapies for treating bladder cancer patients worldwide. This is driving research and development efforts aimed at developing new treatments for this indication..
Scope Of The Report
Report Attributes
Report Details
Report Title
Bladder Cancer Therapeutics and Diagnostics Market Research Report
By Type
Chemotherapy, Immunotherapy, Radiation Therapy, Others
By Application
Hospitals, Oncology Treatment Centers, Ambulatory Surgery Centers, Others
By Companies
Pfizer, GlaxoSmithKline, Merck, Novartis, Bristol-Myers Squibb, Eli Lilly, Roche, Sanofi, AstraZeneca, Celgene Corporation
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
156
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Bladder Cancer Therapeutics and Diagnostics Market Report Segments:
The global Bladder Cancer Therapeutics and Diagnostics market is segmented on the basis of:
Types
Chemotherapy, Immunotherapy, Radiation Therapy, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Oncology Treatment Centers, Ambulatory Surgery Centers, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- GlaxoSmithKline
- Merck
- Novartis
- Bristol-Myers Squibb
- Eli Lilly
- Roche
- Sanofi
- AstraZeneca
- Celgene Corporation
Highlights of The Bladder Cancer Therapeutics and Diagnostics Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Chemotherapy
- Immunotherapy
- Radiation Therapy
- Others
- By Application:
- Hospitals
- Oncology Treatment Centers
- Ambulatory Surgery Centers
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Bladder Cancer Therapeutics and Diagnostics Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Bladder cancer therapeutics and diagnostics are treatments and tests that can help improve the quality of life for people with bladder cancer. These treatments may include surgery, chemotherapy, radiation therapy, or a combination of these therapies.
Some of the major players in the bladder cancer therapeutics and diagnostics market are Pfizer, GlaxoSmithKline, Merck, Novartis, Bristol-Myers Squibb, Eli Lilly, Roche, Sanofi, AstraZeneca, Celgene Corporation.
The bladder cancer therapeutics and diagnostics market is expected to grow at a compound annual growth rate of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Bladder Cancer Therapeutics and Diagnostics Market Overview 4.1 Introduction 4.1.1 Market Taxonomy 4.1.2 Market Definition 4.1.3 Macro-Economic Factors Impacting the Market Growth 4.2 Bladder Cancer Therapeutics and Diagnostics Market Dynamics 4.2.1 Market Drivers 4.2.2 Market Restraints 4.2.3 Market Opportunity 4.3 Bladder Cancer Therapeutics and Diagnostics Market - Supply Chain Analysis 4.3.1 List of Key Suppliers 4.3.2 List of Key Distributors 4.3.3 List of Key Consumers 4.4 Key Forces Shaping the Bladder Cancer Therapeutics and Diagnostics Market 4.4.1 Bargaining Power of Suppliers 4.4.2 Bargaining Power of Buyers 4.4.3 Threat of Substitution 4.4.4 Threat of New Entrants 4.4.5 Competitive Rivalry 4.5 Global Bladder Cancer Therapeutics and Diagnostics Market Size & Forecast, 2020-2028 4.5.1 Bladder Cancer Therapeutics and Diagnostics Market Size and Y-o-Y Growth 4.5.2 Bladder Cancer Therapeutics and Diagnostics Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Chemotherapy
5.2.2 Immunotherapy
5.2.3 Radiation Therapy
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Oncology Treatment Centers
6.2.3 Ambulatory Surgery Centers
6.2.4 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Bladder Cancer Therapeutics and Diagnostics Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Bladder Cancer Therapeutics and Diagnostics Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Chemotherapy
9.6.2 Immunotherapy
9.6.3 Radiation Therapy
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Oncology Treatment Centers
9.10.3 Ambulatory Surgery Centers
9.10.4 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Chemotherapy
10.6.2 Immunotherapy
10.6.3 Radiation Therapy
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Oncology Treatment Centers
10.10.3 Ambulatory Surgery Centers
10.10.4 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Chemotherapy
11.6.2 Immunotherapy
11.6.3 Radiation Therapy
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Oncology Treatment Centers
11.10.3 Ambulatory Surgery Centers
11.10.4 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Chemotherapy
12.6.2 Immunotherapy
12.6.3 Radiation Therapy
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Oncology Treatment Centers
12.10.3 Ambulatory Surgery Centers
12.10.4 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Chemotherapy
13.6.2 Immunotherapy
13.6.3 Radiation Therapy
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Oncology Treatment Centers
13.10.3 Ambulatory Surgery Centers
13.10.4 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Bladder Cancer Therapeutics and Diagnostics Market: Competitive Dashboard
14.2 Global Bladder Cancer Therapeutics and Diagnostics Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 GlaxoSmithKline
14.3.3 Merck
14.3.4 Novartis
14.3.5 Bristol-Myers Squibb
14.3.6 Eli Lilly
14.3.7 Roche
14.3.8 Sanofi
14.3.9 AstraZeneca
14.3.10 Celgene Corporation